This company has been marked as potentially delisted and may not be actively trading. ERYTECH Pharma (ERYP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock ERYP vs. PLX, IKT, IZTC, CVM, ZIVO, CRTX, JATT, ALVR, FNCH, and AIMShould you be buying ERYTECH Pharma stock or one of its competitors? The main competitors of ERYTECH Pharma include Protalix BioTherapeutics (PLX), Inhibikase Therapeutics (IKT), Invizyne Technologies (IZTC), CEL-SCI (CVM), ZIVO Bioscience (ZIVO), Cortexyme (CRTX), JATT Acquisition (JATT), AlloVir (ALVR), Finch Therapeutics Group (FNCH), and AIM ImmunoTech (AIM). These companies are all part of the "medical" sector. ERYTECH Pharma vs. Its Competitors Protalix BioTherapeutics Inhibikase Therapeutics Invizyne Technologies CEL-SCI ZIVO Bioscience Cortexyme JATT Acquisition AlloVir Finch Therapeutics Group AIM ImmunoTech ERYTECH Pharma (NASDAQ:ERYP) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership. Which has preferable valuation & earnings, ERYP or PLX? Protalix BioTherapeutics has higher revenue and earnings than ERYTECH Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioERYTECH Pharma$32.66M3.24-$240KN/AN/AProtalix BioTherapeutics$61.95M2.51$8.31M$0.0727.86 Which has more volatility and risk, ERYP or PLX? ERYTECH Pharma has a beta of 2.69, suggesting that its share price is 169% more volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of -0.23, suggesting that its share price is 123% less volatile than the S&P 500. Is ERYP or PLX more profitable? ERYTECH Pharma has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. ERYTECH Pharma's return on equity of 0.00% beat Protalix BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ERYTECH PharmaN/A N/A N/A Protalix BioTherapeutics -21.03%-30.89%-11.74% Does the media prefer ERYP or PLX? In the previous week, Protalix BioTherapeutics had 1 more articles in the media than ERYTECH Pharma. MarketBeat recorded 1 mentions for Protalix BioTherapeutics and 0 mentions for ERYTECH Pharma. Protalix BioTherapeutics' average media sentiment score of 0.78 beat ERYTECH Pharma's score of 0.00 indicating that Protalix BioTherapeutics is being referred to more favorably in the news media. Company Overall Sentiment ERYTECH Pharma Neutral Protalix BioTherapeutics Positive Do analysts prefer ERYP or PLX? Protalix BioTherapeutics has a consensus price target of $15.00, suggesting a potential upside of 669.23%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Protalix BioTherapeutics is more favorable than ERYTECH Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ERYTECH Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals hold more shares of ERYP or PLX? 1.1% of ERYTECH Pharma shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 1.9% of ERYTECH Pharma shares are held by company insiders. Comparatively, 6.5% of Protalix BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryProtalix BioTherapeutics beats ERYTECH Pharma on 9 of the 14 factors compared between the two stocks. Get ERYTECH Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ERYP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ERYP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERYP vs. The Competition Export to ExcelMetricERYTECH PharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$105.77M$291.50M$5.73B$10.31BDividend YieldN/AN/A5.90%4.63%P/E RatioN/AN/A75.8626.51Price / Sales3.24431.33528.72123.58Price / CashN/A22.4437.1760.46Price / Book3.8810.4412.796.29Net Income-$240K-$111.61M$3.28B$270.51M ERYTECH Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERYPERYTECH PharmaN/A$3.10flatN/AN/A$105.77M$32.66M0.0049PLXProtalix BioTherapeutics2.3241 of 5 stars$1.71-0.9%$15.00+779.8%+78.9%$135.94M$61.95M-13.12200Positive NewsIKTInhibikase Therapeutics1.3197 of 5 stars$1.61-3.9%$6.50+305.0%+34.5%$119.60MN/A-0.606IZTCInvizyne TechnologiesN/A$11.76-2.0%N/AN/A$73.52MN/A0.0029Gap DownCVMCEL-SCI1.3257 of 5 stars$10.00-6.5%N/A-73.0%$68.82MN/A-20.8343Positive NewsShort Interest ↓ZIVOZIVO Bioscience0.3447 of 5 stars$13.96+3.4%N/A+2.4%$53.29M$15.85K-2.8610Gap DownCRTXCortexymeN/A$1.61+2.5%N/A+117.7%$48.54MN/A-0.5455JATTJATT AcquisitionN/A$2.20-0.5%N/A-48.1%$37.95MN/A0.003High Trading VolumeALVRAlloVirN/A$4.68+0.9%N/A-78.8%$23.60MN/A-0.23110Gap DownHigh Trading VolumeFNCHFinch Therapeutics Group1.3961 of 5 stars$12.67-0.2%N/A+7.8%$20.35MN/A-1.44190Negative NewsShort Interest ↓Gap DownAIMAIM ImmunoTech1.7932 of 5 stars$2.58+0.2%$275.00+10,579.6%-91.6%$6.98M$121K-5.4820News Coverage Related Companies and Tools Related Companies PLX Alternatives IKT Alternatives IZTC Alternatives CVM Alternatives ZIVO Alternatives CRTX Alternatives JATT Alternatives ALVR Alternatives FNCH Alternatives AIM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ERYP) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ERYTECH Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share ERYTECH Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ERYP Stock Alerts